Among the different classes of targets, multiple drugs that target HDACs were identified as having the ability to significantly inhibit meningioma growth, suggesting that HDAC inhibition is a promising therapeutic modality for the treatment of meningiomas. The gene discussed is HDAC9; the disease is meningioma.